IAEM Clinical Guideline

The Use of Tranexamic Acid in Trauma Patients

Version 2

Published date: 27th September 2015

Last Updated: 23rd February, 2021

Authors: Dr Áine Mitchell, Dr Ciaran Browne, Gavin Whelan, Dr Una Kennedy

Guideline Leads: Dr Termizi Hassan, IAEM Clinical guideline Development Committee in collaboration with St James’s Hospital

DISCLAIMER

IAEM recognises that patients, their situations, Emergency Departments and staff all vary. These guidelines cannot cover all clinical scenarios. The ultimate responsibility for the interpretation and application of these guidelines, the use of current information and a patient's overall care and wellbeing resides with the treating clinician.
GLOSSARY OF TERMS

Significant haemorrhage
Any patient with Class II-IV haemorrhage as per the Advanced Trauma Life Support (ATLS) classification of haemorrhage.

At risk of significant haemorrhage
Includes any patient who may have compensated haemorrhage or any patient at risk of re-bleeding.

GLOSSARY OF ABBREVIATIONS

ED
Emergency Department

CRASH-2
Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage -2

DIC
Disseminated Intravascular Coagulation

NACL
Sodium Chloride

RCT
Randomised Control Trial

SR
Systematic Review

TBI
Traumatic Brain Injury

TXA
Tranexamic Acid
The Use of Tranexamic Acid in Trauma Patients

INTRODUCTION

This guideline aims to act as a resource for medical and nursing staff and other members of the multidisciplinary Emergency Department team to aid in the use of tranexamic acid (TXA) in trauma patients. This guideline is not intended to replace clinical judgement.

Trauma is the leading cause of death in Ireland in young people, and the third leading cause of death in Ireland overall. Each year, approximately 3 million people die worldwide as a result of trauma, many after reaching hospital. In trauma patients who survive to reach hospital, exsanguination is a common cause of death. Central nervous system injury and multi-organ failure account for most of the remainder, both of which can be exacerbated by severe bleeding.

Anti-fibrinolytic agents have been shown to reduce blood loss in surgical patients without increasing the risk of post-operative complications and have been in long-term clinical use in multiple surgical specialties, particularly cardiothoracic surgery.

Use of TXA is advised in trauma patients with known or suspected major bleeding, within three hours of injury. This is based largely on data published in 2010 from the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial. This trial showed that administration of TXA to trauma patients with significant haemorrhage reduces the risk of death due to bleeding by 15% without increasing the risk of adverse events.

Following the CRASH-2 trial, further trials and systematic reviews have looked at the use of TXA in bleeding trauma patients. In highly developed trauma systems, the mortality benefit of TXA demonstrated in the CRASH-2 trial is likely lessened in clinical practice by other factors
such as early availability of blood products and the ability to perform damage control resuscitation and damage control surgery. Notwithstanding, TXA is known to be safe and beneficial to bleeding trauma patients.

International guidance based on Grade 1A evidence recommends that TXA be administered as early as possible (within three hours) to the trauma patient who is bleeding or at risk of significant haemorrhage at a loading dose of 1g infused over 10 minutes, followed by an intravenous infusion of 1g over 8 hours.
PARAMETERS

Target audience  This guideline is intended for use by Emergency Medicine clinicians involved in the early management of patients with trauma.

Patient population  Trauma patients with suspected significant haemorrhage, or those at risk of significant haemorrhage, seen within 3 hours of trauma.

Exclusion criteria  Patients who are 3 or more hours post-trauma, as administration of TXA does not show any benefit outside of 3 hours and may cause harm.

Contraindications  Hypersensitivity to TXA or any of its excipients, acute venous or arterial thrombosis.

Relative Contraindications  History of convulsions, severe renal impairment, DIC.

AIMS

To ensure the use of TXA in all trauma patients with known or suspected significant haemorrhage as part of their ED management. As a rule of thumb, any trauma patient on whom you draw a transfusion blood sample should be given TXA.

TXA 1g should be administered over 10 minutes within 3 hours of injury, followed by a further dose of TXA 1g infused over 8 hours.
Figure 1. Algorithm for use of TXA in trauma

Clinical suspicion of significant haemorrhage / risk of same

Within 3hrs of injury

Yes

Contraindications to TXA:
1. > 3 hours since injury
2. Hypersensitivity to TXA
3. Acute venous or arterial thrombosis
4. History of convulsion
5. Severe renal impairment

No

Do not administer TXA

ADULT
Administer TXA 1 gram IV (diluted in 100ml of NaCl 0.9%) over 10 minutes; followed by TXA 1 gram IV infusion over 8 hours (in 500ml NaCl 0.9%)

PAEDIATRIC
Administer TXA 15mg/kg (max 1g) IV over 10 minutes in a convenient volume of NaCl 0.9%; followed by TXA 2mg/kg/hr IV infusion for at least 8 hours (suggested dilution for infusion: 500mg in 500 ml of NaCl 0.9% given at the rate of 2ml/kg/hr)

Do not administer TXA

No

Administer TXA
SPECIAL CONSIDERATIONS

Administration in children

TXA is safely used in paediatric surgery. Specific paediatric data for its use in trauma is not currently available, and the available guidance is extrapolated from adult studies.

Paediatric weight adjusted doses are based on Royal College of Paediatrics and Child Health recommendations.

Administration in pregnancy

TXA is safely used in pregnancy and in the postpartum period for indications other than trauma (United States Food and Drug Administration Pregnancy category B). Specific data for TXA use in trauma in this population is not currently available.

Administration to patients with traumatic brain injury (TBI)

Multiple RCTs and well conducted SRs now exist on use of TXA in traumatic brain injury. Data shows that its use in this population is safe. Some data shows a not-statistically significant improvement in patient outcomes. Available evidence does not show a clear improvement in this patient population.

TXA should be administered within 3 hours of injury to all trauma patients with known or suspected significant haemorrhage, including those with known of suspected TBI.

TXA can be considered for patients with isolated TBI within 3 hours of injury.
Renal dosing

Dose adjustment in renal impairment is not necessary due to the short course of treatment.

2g Dosing

Local guidelines exist using TXA 2g bolus dosing. This does not currently have evidence.

COMPANION DOCUMENT

- References